Autonomic neuroscience : basic & clinical · 2001
Development of obesity and neurochemical backing in aurothioglucose-treated mice.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kishi E, Takahashi A, Ishimaru H, Ikarashi Y, Maruyama Y
Аннотация
To clarify the neurochemical backing of aurothioglucose (ATG)-induced obesity in mice, we investigated lesion sites, hypothalamic neurotransmitters and c-Fos-like immunoreactivity (Fos-IR). At day 2 after ATG, tissue loss or cells death was observed in several parts of the ventral area of the ventromedial hypothalamic nucleus (VMH), and the dorsal area of arcuate nucleus and in the nucleus of the solitary tract (NTS). However, the greater part of the VMH was retained. Body weight began to increase in week 1. Hypothalamic serotonin (5-HT) and the metabolites were increased at day 2. The contents of acetylcholine, norepinephrine and dopamine in the hypothalamus showed no significant change. In week 1, the area shown tissue loss was compacted and plugged up. In the control group, most obvious c-Fos-like immunoreactive region was paraventricular nucleus (PVN). At day 2, Fos-IR was observed around destroyed regions in the hypothalamus and NTS, but few Fos-IR was found in the other regions including PVN. The Fos-IR around destroyed regions diminished after week 1. In week 3, Fos-IR in the PVN increased. These results suggest that the development of ATG-induced obesity cannot be attributed to solely VMH destruction. The restoration processes of the neuronal dysfunction involving PVN seem to play an important role in the development of obesity. NTS lesion and 5-HT system might contribute to decrease in food intake for several days after ATG.
Предметные рубрики MeSH
3,4-Dihydroxyphenylacetic AcidAcetylcholineAnimalsAntineoplastic Combined Chemotherapy ProtocolsAntirheumatic AgentsAurothioglucoseBrain ChemistryCytarabineDaunorubicinHomovanillic AcidHydroxyindoleacetic AcidMaleMercaptopurineMiceNorepinephrineObesityParaventricular Hypothalamic NucleusPrednisoloneProto-Oncogene Proteins c-fosSerotoninSolitary NucleusVentromedial Hypothalamic NucleusVincristine